MARKET ROUNDUP FOR 14TH MAY 2007

As mention morninig the stock indices and overall mkt ended on firm note. Suggesting party is not over yet.The market surged today on firm global markets, strong Q4 March 2007 results announced by the State Bank of India (SBI) on Saturday 12 May 2007, and on prospects of political stability in Uttar Pradesh. But the Sensex came off the higher level after an initial 229.86-point rally that took it above 14,000 to 14,026.02. BSE clocked a turnover of Rs 4117 crore compared to Rs 4446.79 crore on Friday, 11 May 2007
Where as nifty closed on 4134.30 net gain of 1.41%
Stocks which are in limelight are - SBI, TATA STEEL, GUJ AMBUJA CEM, RELIANCE IND, RELIANCE CAPITAL

HIGHLIGHTS OF THE MARKET
-Major gainer Matrix lab moved up by rs 23.75 to 224.15 rise of 11%(see todays live mkt sectionb for matrix labs report)
-reliance capital rose to 815.50 rise of 3.26%, i hav given 1000 target foir long term
-my another stock Guj ambuja cem rose 123.70 gain of 3.47% on good monsoon report
-Praj ind- rose 6% to 498 level , it is performing very good
-Moser baer infact declined today to 378.65 level
-Reliance petro stock had come in limelight and moved 6.31%up at 91.80 level, this is long term share, on dip keep buying , 3yrs hav to wait

STOCK TO WATCH-
Matrix labs- The counter saw volumes of 4.92 lakh shares on BSE
Mylan Laboratories is now the foreign promoter of Matrix Laboratories, holding 71% stake in it.
The Pennsylvania-based pharma company Mylan is paying more than its own market value to buy a unit with annual sales almost double its own. It outstripped Teva Pharmaceuticals Industries of Israel, the world's largest maker of generic drugs, in a four-month battle. In August 2006, Mylan acquired a 51% stake in Matrix Laboratories from promoter N. Prasad and a couple of investment outfits. This riggered an open offer for acquiring an additional 20% stake in Matrix. The offer, at Rs 306 per share, closed on 11 December 2006. It suffered steep fall of 85.10% in net profit to Rs 6.66 crore in the quarter ended December 2006 compared with Rs 44.70 crore in the corresponding quarter of 2005. Net sales, too, dipped 1.80% to Rs 174.06 crore, from Rs 177.34 crore.
it has good company and created lots of wealth for investors, yesterdays news had played good punch for the stock. Mylen lab fourth largest generic drug player in the world market got Mercks generic business for $6.6bn , The deal follows Mylan's recent $736m acquisition of a 71.5% stake in Indian-based drug ingredient maker Matrix Laboratories. So Matrix got the new market which will beneficial for company, If Mylan can bet on Matrix why not we retail investors . .

Dabur pharma- Stock has gone down today to 89.90, the support of 92 was broken , good to buy at current level, company had given robust qurter, so decline is only new opportunity to enter the stock.